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Abstract: Mucins have been shown to be aberrantly overexpressed in various diseases including cystic fibrosis,
asthma, and cancer. Recent studies have uncovered the roles of these mucins in the pathogenesis of cancer. The
presence of MUC-1 has also been detected on the cell surface of multiple myeloma (MM) cells in peripheral
blood and showed direct correlation with tumor mass. In this study, we evaluated the levels of soluble MUC-1
(sMUC-1) in 50 new MM patients and correlated this with the levels of sMUC-1 after treatment. High levels of
sMUC-1 were found in 20/50 (40%) MM patients, and in 2/50 (4%) healthy individuals (p = 0.001). According
to the ISS, we found significant differences of mean sMUC-1 levels between the first stage of the disease (0.63 ±
± 0.26) and the third (0.93 ± 0.24; p = 0.03), but not with the second stage (0.80 ± 0.22; p = 0.08). Our study
confirmed the correlation between elevated sMUC-1 and high elevated lactate dehydrogenase (p = 0.03) and
the level of IgG in groups of patients with MM IgG at every stage of disease (p = 0.001). We showed for the first
time that levels of sMUC-1 after treatment, in a group of patients with initially elevated levels of MUC-1, were
statistically lower than in a group of patients with initially lower levels of sMUC-1 (21% vs. 42,6%; p = 0.05). At
37 months median of follow-up, we found a statistically significant difference between patients with normal
versus elevated sMUC-1 in terms of progression-free survival (median 12 months vs. 8.1 months; p = 0.03).
(Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 654–658)
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Introduction
MUC-1 is a highly glycosylated transmembrane pro-
tein, with high molecular weight. It is produced by
ductal epithelial cells and normally presents on the
luminal surface of secretory glands [1]. A soluble form
of MUC-1 (sMUC-1, CA 15.3 CA27.29 antigen) has
been found in breast milk, peripheral blood, urine,
and supernatants from cultures of MUC-1+ cancer
cell lines and primary cancer cells [1–4]. Increased
levels of sMUC-1 have been detected in many ade-
nocarcinomas, such as breast, ovary, pancreas and
lung, and seem to correlate with tumor burden [5–7].
The level of sMUC-1 has been declared by the FDA
(US Food and Drug Administration) to be a useful
marker in monitoring disease activity for breast can-
cer patients. The function of MUC-1 remains to be
defined. From an immunologic standpoint, both an
immunostimulatory [8–10] and an immunoinhibitory
[11, 12] role have been proposed. MUC-1 disturbs
cell–cell interaction, inhibits aggregation in vitro, and
decreases the activity of natural killer cells and lym-
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phokine activated killer cells in cancer tissues
[13–15]. Mucins have been shown to contain complex
associations with various cellular pathways, impacting
cell growth, proliferation, and apoptosis. Historically,
transformation events in cancer have been defined as
initiation events (contributing to the early stages of
neoplastic transition) or progression events (referring
to the subsequent transformative processes) [16]. Us-
ing human tumor xenograft models, MUC-1 has been
shown to cause transformation of fibroblast cells. Also,
the alteration of the tumorigenicity and metastasis of
various cancer cell lines by overexpression and down-
regulation of mucins demonstrates their role in the
pathogenesis of different malignancies [17–19]. Recent
studies have suggested that MUC-1 modulates various
pathways contributing to cell growth. MUC-1 directly
binds to the p53 regulatory domain and selectively pro-
motes transcription of growth arrest genes. It decreases
transcription of apoptotic genes as a survival response
to stress, and thereby decreases cell death [20].
Furthermore, recent studies have suggested that
sMUC-1 may be an important immunosuppressive
agent in patients with MUC-1-bearing malignancies,
as evidenced by the poor response to active specific
immunotherapy in patients with metastatic adenocar-
cinomas who have highly elevated sMUC-1 levels [21].
Therefore, determining sMUC-1 levels in multiple
myeloma (MM) patients may be important from an
immunobiologic standpoint.
The aim of this study was to estimate the level of
sMUC-1, to explore whether there are differences in
sMUC-1 level between patients with different stages
of multiple myeloma and healthy individuals, and to
assess the variation of sMUC-1 during chemothera-
py treatment.
Material and methods
Fifty patients with newly diagnosed MM were studied. The
median age of patients when the samples were obtained was
59 and the range was 40–75. Twenty four of them were fe-
male and 26 were male. The pre-treatment evaluation in-
cluded a complete blood count, albumin in serum, the con-
centration of paraprotein in serum, immunoglobulin class
subtype (Ig) and the levels of calcium, beta-2-microglobu-
lin (b2m), lactate dehydrogenase (LDH) and C-reactive pro-
tein (CRP). Bone marrow aspirates and trephine biopsies
(TB) to detect plasma cells were obtained (Table 1). Pa-
tients at the time of diagnosis were allocated into one of
three groups based on the International Staging System
(ISS): five patients in the first stage, 20 in the second stage,
and 25 in the third stage.
Patients’ initial treatment for multiple myeloma depend-
ed on their age and comorbidities. For patients under the
age of 65, the induction regimens were thalidomide–dex-
amethasone and cyclophosphamide (CTD) prior to autolo-
gous stem-cell transplantation. For patients over 65 and
patients with significant concurrent illness, the standard of
care was chemotherapy with melphalan, prednisone and tha-
lidomide (MPT). Of the 50 patients, 28 were treated with
CTD combination therapy and 22 with MPT therapy. Re-
sponse was assessed after six cycles of chemotherapy ac-
cording to the European, International, and Autologous
Bone Marrow Transplant Registries (EBMT/IBMTR/
/ABMTR) criteria [22].
Informed written consent was obtained from all partic-
ipants and the Ethics Committee of the Medical University
of Bialystok approved the study.
The control group consisted of 50 healthy individuals,
age- and sex-matched.
Assay of MUC-1. Assay of MUC-1 was done according to
the previously published protocol [23].
Samples of human serum were diluted in PBS to pro-
tein concentration 2 μg/mL and aliquots (50 μL) were coat-
ed onto microtiter plates (NUNC F96; Maxisorp, Roskilde,
Denmark) at room temperature overnight. The protein con-
centration was determined using the bicinchoninic acid
method according to the manufacturer’s instructions (BCA
Protein Assay Kit, Pierce, Rockford, IL, USA). The wells
were washed three times (100 μL) with PBS, pH 7.4, 0.05%
Tween (PBS-T; washing buffer) between all ensuing steps.
Unbound sites were blocked with 100 μL of 1% blocking
reagent for ELISA (Roche Diagnostics, Mannheim, Ger-
many) for 1 h. The wells were than incubated for 2 hours
Table 1. Characteristics of MM patients
Mean ± SD
Age 70.82 ± 9.90
Hb [g/dl] 10.56 ± 2.16
Serum Ca [mmol/L] 2.46 ± 0.29
Serum M protein [g/dl] 2.37 ± 2.17
Plasma cells in aspirate (%) 23.11 ± 19.90
Plasma cells in TB (%) 45.18 ± 28.52
IgG [mg/dl] 3331.61 ± 2371.16
IgA [mg/dl] 3260.64 ± 2554.67
IgM [mg/dl] 43.67 ± 44.82
Serum albumin [g/l] 3.94 ± 0.64
b2m [mg/L] 5469.47 ± 3804.62
CRP [mg/L] 6.57 ± 4.53
LDH [IU/I] 201.71 ± 46.90
Hb — hemoglobin; Ca — calcium; M — monoclonal; TB — trephine
biopsy; Ig — immunoglobulin; b2m — beta-2-microglobulin;
CRP — C-reactive protein; LDH — lactate dehydrogenase
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with 100 μL of anti-MUC-1 monoclonal antibody (anti-
-EMA, clone GP1,4; Sigma, St Louis, MO, USA) diluted in
PBS-T/1% BSA (Sigma) 1:500 (v/v). Next, plates were incu-
bated (1 h) with 100 μL of secondary antibody, horseradish
peroxidase conjugatated anti-mouse IgG (Sigma) diluted
in PBS-T/1% BSA 1:1,500 (v/v). Next, plates were washed
four times in PBS, and the colored reaction was developed
by incubating with 2,2'-azino-bis(3-ethylbenzthiazoline-6-
-sulfonic acid) (ABTS) — liquid substrate for horseradish
peroxidase (Sigma). Absorbance at 405 nm was measured
after 30–45 min in an ELISA reader. As controls, wells with
no serum were used.
The assay was performed in triplicate for each serum
and the results are presented as the mean difference be-
tween the reading in optical density units (OD) in experi-
mental wells and controls.
Statistical analysis. Spearman rank correlations or gener-
alized linear modeling was used to assess differences in ab-
sorbance levels (using log-transformed values of absorbance)
for a more quantitative assessment of factors affecting anti-
MUC-1 antibody production. Combinations of factors were
examined to identify the best cumulative index of experienc-
es associated with the likelihood of having antibodies.
The MUC-1 assay methods were compared using one-
way analysis of variance (ANOVA) and t-student test for
dependent and independent samples. The statistical signif-
icance of the measured differences was determined using
an alpha index of 0.05.
Results
The mean levels of sMUC-1 in all patients with MM
and healthy individuals showed no statistically signif-
icant differences (0.81 ± 0.25 vs. 0.78 ± 0.05;
p = 0.38). According to the ISS, we found significant
differences of mean sMUC-1 levels between the first
stage of the disease (0.63 ± 0.26) and the third
(0.93 ± 0.24; p=0.03), but not the second (0.80 ± 0.22;
p = 0.08). Based on previous responses in over 500
cancer cases and controls, absorbance reactions at
> 1.0 were scored as high [5]. The study revealed that
patients with more advanced disease were most like-
ly to have an elevated baseline MUC-1 [first stage,
zero of 5 patients (0%); second stage, eight of 20
(40%) and third stage, 12 of 25 (48%); p = 0.1].
In comparison with the levels of healthy subjects,
high levels of sMUC-1 were found in 20/50 (40%)
MM patients. In the healthy control group, only two
subjects had high levels (4%), and this difference was
statistically significant (p = 0.001).
From the various parameters of MM, we found
statistical correlation with elevated lactate dehydro-
genase (r = 0.71; p = 0.03) and the level of IgG in
groups of patients with MM IgG at every stage of
disease (r = 0.87; p = 0.001). According to the ISS,
in the third group we found significant correlation
between percentage of bone marrow plasma cells
from the smear of the bone marrow (r = 0.73;
p = 0.01), but not with the immunohistochemically
detected percentage of plasma cells from biopsy sam-
ples (r = 0.54; p = 0.375).
In univariate analysis, we found a strong tendency
for higher response rate (RR = patient with partial
response and complete remission) among patients
with normal levels of MUC-1 (RR — 40% vs. 16%
for those with elevated level; p = 0.072). After the
treatment, levels of sMUC-1 from all MM patients
were statistically lower than the levels before the treat-
ment (0.81 ± 0.25 vs. 0.59 ± 0.3; p = 0.001) (Figure 1).
A decrease in the level of sMUC-1 was also found  in
the group of patients with initially higher levels of
sMUC-1 and in those with normal levels. Decreased
levels of sMUC-1 in groups, based on ISS, were: first
stage (0.63 ± 0.26 vs. 0.42 ± 0.13; p=0.0006), second
stage (0.80 ± 0.22 vs. 0.56 ± 0.2; p = 0.00072), and
third stage (0.93 ± 0.24 vs. 0.72 ± 0.13; p = 0.01).
Decreased levels of sMUC-1 after treatment in
a group of patients with initially elevated levels of
MUC-1, were statistically lower than in a group of
patients with initially lower levels of sMUC-1 (21%
to 42,6%; p = 0.05). We did not find statistically sig-
nificant differences between the type of chemothera-
py and the level of sMUC-1 after the treatment.
At 37 months median of follow-up, we found
a statistically significant difference between patients
Figure 1. Reactivity with monoclonal antibodies (sMUC-1)
at 405 nm in multiple myeloma patients before and after
treatment
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with normal versus elevated sMUC-1 in terms of pro-
gression-free survival (median 12 months vs. 8.1
months; p = 0.03).
Discussion
Multiple myeloma is an ‘indolent’ disease. Even
though its disease progression seems to be somewhat
slower and less aggressive than other hematologic
malignancies, a complete cure can hardly be achieved
by standard chemotherapy or even by bone marrow
transplantation. MUC-1 is of particular interest be-
cause it is a diagnostic marker that exists as an integral
membrane glycoprotein and as shed forms, and because
it is a therapeutic target for both cell-mediated and
antibody-based immunotherapeutic strategies.
Although most of the work to date with this tar-
get antigen has been in breast and pancreatic can-
cers, a few reports have shown that sMUC-1 can be
detected in the serum of MM patients [24]. The pres-
ence of MUC-1 on the cell surface of MM cells has
been identified, as well, by several investigators
[25–27]. It has also been shown that patients with
MM have high peripheral blood and bone marrow
levels of MUC-1, and that the latter directly corre-
late with tumor mass [27]. Treon et al. [27] found
that dexamethasone (Dex) induces MUC-1 expres-
sion on MM cell lines. On the other hand, Durum et
al. [28] found that stimulation of MM cells with
IL-7 is associated with increases in MUC-1 expres-
sion at the mRNA and protein levels.
Similarly to the studies of Luminari et al. [26] and
Mileshkin et al. [29], we were unable to demonstrate
a statistically significant difference between the
sMUC-1 from MM patients and healthy individuals,
but we found statistical differences between the first
and third stages. Furthermore, like those studies, we
did not find a correlation between sMUC-1 levels and
various parameters of MM, but we confirmed the sta-
tistically significant correlation, observed by Luminari
et al. [26], between elevated sMUC-1 and elevated
lactate dehydrogenase but not with anemia. Increased
sMUC-1 level is correlated with features associated
with high tumor burden, such as high serum lactate
dehydrogenase. Similarly to Treon et al. [30] and Lu-
minari et al. [26], we demonstrated that patients with
more advanced disease were most likely to have an
elevated baseline sMUC-1. Although these malignant
cells may be the source of sMUC-1, it also remains
possible that MM cells trigger release of sMUC-1 from
other cells which contribute, at least in part, to the
elevated sMUC-1 levels found in MM patients. Our
findings showed that sMUC-1 levels are elevated in
plasma patient samples, especially in a group of pa-
tients in ISS third stage.
Furthermore, Luminari et al. [26], based on the
fact that high levels of sMUC-1 are very frequently
associated with a diagnosis of plasma cell leukemia
and indicate a possible relationship between them and
tumor malignancy (cell proliferation through growth
factor receptor, b-catenin and ERa, and suppressing
apoptosis through the regulation of JNK, NF-kB,
HSP90, and extrinsic apoptotic pathways), have sug-
gested that the initial level of sMUC-1 may have
a role in tumor progression of MM patients [20, 31].
In our study, at 37 months median of follow-up, we
found a statistically significant difference between
patients with normal versus elevated sMUC-1 in terms
of progression-free survival. These results suggest that
sMUC-1 can be considered to be an independent
prognostic factor in MM patients.
Therefore, antibodies against MUC-1 may be po-
tential candidates for patient-adapted, antibody-me-
diated immunotherapy in MM. In addition, this ob-
servation might also contribute to cellular immunity,
because sMUC-1 specific T cells against under-glyc-
osylated forms have been demonstrated in MM pa-
tients [32].
If the aforementioned mucin interactions are re-
quired to promote tumor progression, then it could
be useful to target these interactions for the treat-
ment of cancer. Furthermore, the disruption of these
interactions would elucidate the contribution of each
process, and the intervention of these pathways may
be helpful in controlling tumor progression.
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